Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics (Nasdaq: TRVI) announced statistically significant data from its Phase 2 CANAL trial of Haduvio (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF). The trial demonstrated a 76.1% reduction in 24-hour cough frequency for nalbuphine ER subjects versus 25.3% for placebo (p<0.0001). Key secondary endpoints also showed significant improvement. The results will be presented at the British Thoracic Society's Winter Meeting in London on November 23, 2022. Chronic cough affects over a million patients globally, highlighting the importance of effective treatments.
Summary not available.
Trevi Therapeutics announced the pricing of its underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $50 million. The offering is led by SVB Securities, Stifel, and Oppenheimer & Co. and expected to close on September [__], 2022, pending customary conditions. The shares are sold under a shelf registration statement filed with the SEC. Trevi’s investigational therapy, Haduvio, addresses chronic cough in idiopathic pulmonary fibrosis and prurigo nodularis, with the offering intended to bolster its clinical development efforts.
Trevi Therapeutics has announced a public offering of its common stock and pre-funded warrants to purchase common stock. The offering, managed by SVB Securities, Stifel, and Oppenheimer & Co., is subject to market conditions, with a 30-day option for underwriters to purchase additional shares. The offering is made under a shelf registration statement filed with the SEC, and preliminary terms will be detailed in a forthcoming prospectus supplement. Trevi focuses on developing Haduvio, an investigational therapy for chronic cough and prurigo nodularis.
Trevi Therapeutics (Nasdaq: TRVI) announced positive results from its Phase 2 CANAL trial of Haduvio, an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis. The trial showed a significant reduction in daytime cough frequency, with a 75.1% decrease compared to 22.6% for placebo (p<0.0001). Secondary endpoints also demonstrated consistent efficacy across patient-reported outcomes. The results were consistent with the interim analysis, and the company plans to initiate the next clinical trial in early 2023, as there are no approved therapies for chronic cough in IPF patients.
Trevi Therapeutics, a clinical-stage biopharmaceutical company, announced that its CEO, Jennifer Good, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:30 AM ET. The presentation will highlight the investigational therapy Haduvio™ (oral nalbuphine ER), aimed at treating prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis. Trevi is focused on the development of Haduvio, which has received Fast Track designation from the FDA.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced a virtual R&D Day scheduled for September 19, 2022, from 10 AM to 12:30 PM ET. The event will feature expert presentations from Dr. Peter Dicpinigaitis and Dr. Brian Kim, focusing on chronic cough and prurigo nodularis. Trevi will provide updates on its investigational therapy Haduvio (oral nalbuphine ER), which aims to address unmet needs in these conditions. Participants can register and access a live webcast of the event.
Trevi Therapeutics, Inc. (TRVI) announced that two late-breaking abstracts have been accepted for oral presentations at upcoming medical conferences. The European Respiratory Society International Congress 2022, held in Barcelona from September 4-6, will feature data from the Phase 2 CANAL trial on the use of Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF). Similarly, the EADV Congress in Milan from September 7-10 will present findings from the Phase 2b/3 PRISM trial on prurigo nodularis. Both trials reported statistically significant efficacy results.
Trevi Therapeutics reported positive results from the Phase 2b/3 PRISM trial of its investigational therapy, Haduvio™, for treating Prurigo Nodularis. The trial achieved its primary endpoint, with 25% of Haduvio patients showing a significant reduction in itch compared to 14% on placebo (p=0.0157). The company completed a $55 million private placement to support further clinical development. For Q2 2022, Trevi's total cash was $78.9 million, with a net loss of $8.1 million, improved from $9.8 million in Q2 2021.
Future data from the Phase 2 CANAL trial on chronic cough is expected later this quarter.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) announced its participation in two key conferences in August 2022. On August 16, CEO Jennifer Good will engage in a fireside chat at the Stifel Biotech Executive Summer Summit. On August 29, CMO Thomas Sciascia and Professor Toby Maher will co-host a workshop at the 6th Annual IPF Summit in Boston, emphasizing chronic cough treatment strategies. Trevi's investigational therapy Haduvio is being developed for prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis, with FDA Fast Track designation for itch treatment.